This 2021 rodent study investigated effects of Vitamin K2 on salt-sensitive hypertension:
“Mice were supplemented with VK2 and gut bacteria were detected by 16S rRNA. Common signaling pathway-related proteins were detected to further verify signaling pathways before validation of clinical samples.
Diets for 4 weeks were:
- Normal group diet containing 0.5% NaCl;
- High salt group (HS) diet containing 8% NaCl;
- High salt diet plus VK2 supplementation group (HS_VK2) diet containing 8% NaCl and additional 0.025% VK2.
VK2 supplementation protected blood pressure and aortic vessels in salt-induced mice:
VK2 treated salt-sensitive hypertension by inhibiting the renin–angiotensin system.
Possible mechanisms of VK2 for salt-sensitive hypertension.”
https://www.frontiersin.org/articles/10.3389/fnut.2021.639467/full “Network and 16S rRNA Sequencing-Combined Approach Provides Insightal Evidence of Vitamin K2 for Salt-Sensitive Hypertension”
The form of Vitamin K2 was MK-4 per its C31H40O2 molecular formula. Data wasn’t provided to calculate a human-equivalent dose for 0.025% MK-4.
This study was part of a 2022 Gut Microbial Response to Host Metabolic Phenotypes collection which included animal studies investigating gut microbiota in contexts of β-carotene and β-sitosterol supplementation. I found this collection by it citing the 2018 rodent study GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose which was Reference 27 of Dr. Paul Clayton’s blog post Sweet Nothing.